News

PhD student position open in CRISPR gene therapy group

We’re happy to announce an open PhD student position at our lab, focusing on developing gene correction strategies for inborn errors of immunity. The role is perfect for MScs with a year or two of work experience after graduation and who have experience with immunology. 

Find the related information below, and get in touch if you’re interested in this position or would like any further details. 😊

About the position

This is a three-year PhD research fellowship position at our lab, located at NCMBM (Norwegian Centre for Molecular Biosciences and Medicine) at the University of Oslo & Oslo University hospital.

Work tasks

The focus will be on optimizing and scaling up protocols for efficient mutation correction in human T cells and hematopoietic stem cells, and transplanting cells to mouse models. We use both patient samples and healthy control cells. Example tasks:

Required qualifications

We are looking for an enthusiastic and hard-working scientist with a Masters degree or equivalent in life sciences. We prioritize candidates with work experience in academic or private research environments, in the fields of stem cell biology, immunology, gene editing or high-throughput screening. The research fellow will take part in an approved PhD program at the University of Oslo and is expected to complete the project within the set fellowship period, leading to the successful completion of a PhD degree. Fluent oral and written communication skills in English are mandatory.

How to apply?

If this sounds like you, please go ahead and apply – we look forward to hearing from you! Applications are done through Jobbnorge.

If you’d like to ask us anything before applying, please contact us.

Latest news

Our group has an open position for a 3-year PhD research fellow!
The 3-day winter retreat took place at the Dr. Holms hotel in Geilo, Norway.
This collaborative grant will enable our work towards developing innovative nanotechnology-based systems to support stem cell viability and advance gene editing therapies.
It was a comprehensive, 5-day workshop that took place in Leuven in November 2024.